<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stratton, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutational Signatures in Human Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-5</style></pages><abstract><style  face="normal" font="default" size="100%">To date, 10 000 to 20 000 cancer genomes have been fully or partially sequenced. Cancer genome sequences could prove crucial in predicting therapy outcome and response and could allow the development of assays that detect sequence fragments that leak out of cancer cells. It is hoped that these fragments will prove to be diagnostic hallmarks. This article discusses the mutational signatures of human cancer.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>